Lung Cancer Drug Motesanib Fails Late-Stage Trial

The phase III MONET-A study has failed to meet its primary endpoint in patients with stage IV non-squamous non-small-cell lung cancer who were randomly assigned to treatment with motesanib in combination with paclitaxel and carboplatin compared with placebo plus paclitaxel and carboplatin. As a result, the study has been terminated.

http://ift.tt/19tg5HI